The PPARγ-FGF1 axis: An unexpected mediator of adipose tissue homeostasis

Touchstone Diabetes Center, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA.
Cell Research (Impact Factor: 12.41). 06/2012; 22(10):1416-8. DOI: 10.1038/cr.2012.94
Source: PubMed


Adipose tissue remodeling is a dynamic process during nutritional fluctuation that plays critical roles in metabolic homeostasis and insulin sensitivity. The process is highly regulated by many factors, including adipokines and cytokines that are locally released within fat pads. In a recent study published in Nature, Jonker and colleagues identified FGF1 as an important mediator that is selectively induced in fat cells by high-fat diet feeding and established the PPARγ-FGF1 axis as a critical pathway that regulates adipose tissue remodeling and ultimately systemic metabolic homeostasis.

Download full-text


Available from: Kai Sun,
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Thiazolidinediones (TZDs) are potent insulin sensitizers that act through the nuclear receptor peroxisome proliferator-activated receptor-γ (PPARγ) and are highly effective oral medications for type 2 diabetes. However, their unique benefits are shadowed by the risk for fluid retention, weight gain, bone loss and congestive heart failure. This raises the question as to whether it is possible to build a safer generation of PPARγ-specific drugs that evoke fewer side effects while preserving insulin-sensitizing potential. Recent studies that have supported the continuing physiologic and therapeutic relevance of the PPARγ pathway also provide opportunities to develop newer classes of molecules that reduce or eliminate adverse effects. This review highlights key advances in understanding PPARγ signaling in energy homeostasis and metabolic disease and also provides new explanations for adverse events linked to TZD-based therapy.
    Nature medicine 05/2013; 19(5):557-66. DOI:10.1038/nm.3159 · 27.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this study was to investigate the expression of peroxisome proliferator-activated receptor-γ (PPAR-γ) in adipose tissue of the rat model of polycystic ovary syndrome (PCOS), induced by dehydroepiandrosterone (DHEA). Sixteen sexually immature Sprague-Dawley female rats were randomly assigned to the DHEA (n=8) or control (n=8) group. Adipose tissue was collected from the two rat groups following subcutaneous injection of DHEA in the DHEA group and a standard laboratory diet in the control group for 20 consecutive days. Reverse transcription polymerase chain reaction and western blot analysis were performed to detect expression of PPAR-γ at the mRNA and protein level in the adipose tissue. Both PPAR-γ mRNA and protein levels were decreased in the adipose tissue of DHEA‑induced PCOS rats compared to the control group. This decrease was significant (P<0.01). These results suggest that the pathogenesis of PCOS, which shares a number of common features with hyperandrogenemia, may involve the lipid metabolism pathway through inhibition of PPAR-γ.
    Molecular Medicine Reports 01/2014; 9(3). DOI:10.3892/mmr.2014.1895 · 1.55 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Fibroblast growth factor 1 (FGF1) is an autocrine/paracrine regulator whose binding to heparan sulphate proteoglycans effectively precludes its circulation. Although FGF1 is known as a mitogenic factor, FGF1 knockout mice develop insulin resistance when stressed by a high-fat diet, suggesting a potential role in nutrient homeostasis. Here we show that parenteral delivery of a single dose of recombinant FGF1 (rFGF1) results in potent, insulin-dependent lowering of glucose levels in diabetic mice that is dose-dependent but does not lead to hypoglycaemia. Chronic pharmacological treatment with rFGF1 increases insulin-dependent glucose uptake in skeletal muscle and suppresses the hepatic production of glucose to achieve whole-body insulin sensitization. The sustained glucose lowering and insulin sensitization attributed to rFGF1 are not accompanied by the side effects of weight gain, liver steatosis and bone loss associated with current insulin-sensitizing therapies. We also show that the glucose-lowering activity of FGF1 can be dissociated from its mitogenic activity and is mediated predominantly via FGF receptor 1 signalling. Thus we have uncovered an unexpected, neomorphic insulin-sensitizing action for exogenous non-mitogenic human FGF1 with therapeutic potential for the treatment of insulin resistance and type 2 diabetes.
    Nature 07/2014; 513(7518). DOI:10.1038/nature13540 · 41.46 Impact Factor
Show more